# US 2012/0251536 A1 · Biopolymer hybrid gel-depot delivery system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251536 A1
- Document ID: US20120251536A1
- Status: Published application
- Kind: A1
- Application number: 13/382,655
- Filed: 2010-07-09
- Published: 2012-10-04
- Earliest claimed: 2009-07-09
- Assignees: Polymers Crc Ltd.
- Inventors: David Edward Mainwaring; Mohammad Al Kobaisi; Brendon Yew Loong Chua; David Charles Jackson; Weiguang Zeng
- Web page: https://patentgrep.com/patent/US20120251536A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 47/02: Inorganic compounds
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to biopolymer-gel based depot systems for prolonged and/or controlled release delivery of biologically active agents, methods for the manufacture of the biopolymer based gel-depots which include a biologically active agent, and uses of such biopolymer gel-depots in therapy. The biopolymer-gel based depot systems comprise a biocompatible polyaminosaccharide and/or protein; a biocompatible phosphate and/or sulphonamide compound; a biologically active agent; an aqueous insoluble alkaline earth metal phosphate; and a biocompatible glycan and/or proteoglycan.

## Claims

### Claim 1

A prolonged release and/or controlled release delivery system for delivery of a biologically active agent, the system comprising:
(i) a first component comprising a biocompatible polyaminosaccharide and/or protein; and
(ii) a second component comprising a biocompatible phosphate and/or sulphonamide compound capable of cros slinking with the first component,
wherein
(a) the first and/or second components further comprises the biologically active agent; and
(b) the first and/or second components also comprises:
(i) an aqueous insoluble alkaline earth metal phosphate; and/or
(ii) a biocompatible glycan and/or proteoglycan; and
whereby the first and second components of the system are physically isolated and, when in use, combining of the first and second components promotes crosslinking and results in the formation of a biopolymer hybrid gel-depot including the biological active agent.

### Claim 2 (depends on 1)

A delivery system according to claim 1 wherein the biocompatible polyaminosaccharide and/or protein is chitosan or a salt thereof.

### Claim at position 3

3-5. (canceled)

### Claim 6 (depends on 2)

A delivery system according to claim 2 wherein the biologically active agent is conjugated to the chitosan.

### Claim 7 (depends on 1)

A delivery system according to claim 1 wherein the biocompatible phosphate and/or sulphonamide is sodium triphosphate (TPP).

### Claim 8 (depends on 1)

A delivery system according to claim 1 wherein the aqueous insoluble alkaline earth metal phosphate is hydroxyapatite.

### Claim 9 (depends on 1)

A delivery system according to claim 1 wherein the biocompatible glycan and/or proteoglycan is selected from chondroitin sulphate, sodium hyaluronate, and carboxymethyl cellulose.

### Claim 10 (depends on 1)

A delivery system according to claim 1 wherein the biocompatible glycan and/or proteoglycan is a proteoglycan.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

A delivery system according to claim 1 wherein the biological active agent is selected from the group consisting of insulin, cortisol, estrogen or growth hormone infliximab, adalimumab, nituximab, alemtuzumab, daclizumab, basiliximab, etanercept and LHRH.

### Claim at position 11

13-19. (canceled)

### Claim 20 (depends on 1)

A delivery system according to claim 1 wherein the biopolymer hybrid gel-depot including the biological active agent has a Young's modulus in the range of about 20 to 60 kPa.

### Claim 21 (depends on 1)

A delivery system according to claim 1 wherein the biopolymer hybrid gel-depot including the biological active agent has a compressive modulus in the range of about 100 kPa to 500 kPa.

### Claim 22

A method of forming a prolonged release and/or controlled release biopolymer hybrid gel-depot including a biologically active agent, said method comprising:
(i) providing a first component comprising a biocompatible polyaminosaccharide and/or protein, and a second component comprising a biocompatible phosphate and/or sulphonamide compound capable of crosslinking with the first component,
(a) wherein the first and/or second component further comprises the biologically active agent; and
(b) wherein the first and/or second component also comprises:
(i) an aqueous insoluble alkaline earth metal phosphate; and/or
(ii) a biocompatible glycan and/or proteoglycan; and
(ii) combining the first and second components for a time and under conditions to promote crosslinking and to form a biopolymer hybrid gel-depot including the biologically active agent.

### Claim at position 15

23-26. (canceled)

### Claim 27

A biopolymer hybrid gel-depot comprising:
(i) a biocompatible polyaminosaccharide and/or protein;
(ii) a biocompatible phosphate and/or sulphonamide substantially crosslinked to (i);
(iii) an aqueous insoluble alkaline earth metal phosphate;
(iv) a biocompatible proteoglycan; and
(v) a biologically active agent.

### Claim 28

A biopolymer hybrid gel-depot comprising:
(i) chitosan (or a suitably functionalised derivative thereof);
(ii) tripolyphosphate substantially crosslinked to (i);
(iii) hydroxyapatite;
(iv) chondroitin sulphate; and
(v) a biologically active agent.

### Claim at position 18

29-34. (canceled)

### Claim 35

A method of delivering a biologically active agent to a subject including the step of administering:
(i) a first component comprising a biocompatible polyaminosaccharide and/or protein; and
(ii) a second component comprising a biocompatible phosphate and/or sulphonamide compound capable of crosslinking with the first component,
wherein
(a) the first and/or second component further comprises the biologically active agent; and
(b) the first and/or second compounds also comprises:
(i) an aqueous insoluble alkaline earth metal phosphate; and/or
(ii) a biocompatible glycan and/or proteoglycan; and
whereby the first and second components are simultaneously or sequentially injected at the same site.

### Claim 36

A method of delivering a biologically active agent to a subject including the step of implanting a biopolymer hybrid gel-depot comprising:
(i) a biocompatible polyaminosaccharide and/or protein;
(ii) a biocompatible phosphate and/or sulphonamide substantially crosslinked to
(i);
(iii) an aqueous insoluble alkaline earth metal phosphate;
(iv) a biocompatible glycan and/or proteoglycan; and
(v) a biologically active agent.

### Claim 37

(canceled)
